12 To 15 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.5)
  • Patent number: 10172910
    Abstract: Methods of preventing or reducing the incidence of acute urinary retention in mammals susceptible to developing acute urinary retention, and methods of reducing the incidence of clinically detected prostate cancer, using compositions containing compounds based on small peptides and a pharmaceutically acceptable carrier, are described. The methods include, but are not limited to, administering the compounds intramuscularly, orally, intravenously, intraprostatically, intrathecally, intratumorally, intranasally, topically, transdermally, etc., either alone or conjugated to a carrier to a mammal in need thereof.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: January 8, 2019
    Assignee: NYMOX CORPORATION
    Inventor: Paul Averback
  • Patent number: 9789157
    Abstract: A method has been developed of preventing or limiting formation of adhesions by administering to a site in need thereof, in the absence of or after bleeding or leakage of fluid has been substantially stopped, a self-assembling material which forms a barrier to formation of adhesions. In certain embodiments, the self assembling materials are peptidomimetics, nucleotidomimetics, di- and triblock copolymers, N-alkylacrylamides, or dendimers. These materials are also useful in a method for regeneration or repair of tissue or cells forming tissue.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: October 17, 2017
    Assignee: Arch Biosurgery, Inc.
    Inventors: Rutledge Ellis-Behnke, Terrence W. Norchi, Stephen Richard Kelly
  • Patent number: 9650417
    Abstract: The present invention provides pharmaceutical compositions and methods of treating lower gastrointestinal disorders, including irritable bowel syndrome and constipation.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: May 16, 2017
    Assignee: Ironwood Pharmaceuticals, Inc.
    Inventors: Mark G. Currie, Daniel P. Zimmer, Angelika Fretzen, Marco Kessler
  • Publication number: 20150148303
    Abstract: The embodiments are directed to peptides, compositions, and methods of treating conditions requiring removal or destruction of harmful or unwanted cells in a patient, such as benign and malignant tumors, using compounds containing or based on peptides.
    Type: Application
    Filed: November 26, 2013
    Publication date: May 28, 2015
    Applicant: NYMOX CORPORATION
    Inventors: Paul AVERBACK, Jack Gemmell
  • Patent number: 9040481
    Abstract: Methods for treating fatty liver disease, e.g., hepatic steatosis, using peptide fragments of the C-terminal end of glucagon-like peptide-1 (GLP-1), e.g., GLP-1(28-36).
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: May 26, 2015
    Assignee: The General Hospital Corporation
    Inventors: Joel F. Habener, Eva Tomas-Falco
  • Publication number: 20150140060
    Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Inventor: Gautam GHATNEKAR
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150133392
    Abstract: The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and/or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Neel K. KRISHNA, Kenji CUNNION
  • Publication number: 20150125478
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 7, 2015
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
  • Publication number: 20150126461
    Abstract: The present invention relates to a skin-permeating peptide, and more particularly, the present invention relates to an isolated peptide capable of permeating the skin to deliver a drug to the skin, to an isolated polynucleotide coding the peptide, to a composition for transdermal delivery comprising the peptide, and to a peptide/cargo composite comprising the peptide and cargo.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 7, 2015
    Inventor: Seol Hoon Lee
  • Publication number: 20150119340
    Abstract: A fusion peptide including a hydrophobic peptide and a basic peptide, a pharmaceutical composition including the fusion peptide, a cell membrane penetrating conjugate including the fusion peptide and a substance of interest, and a method for intracellular delivery of a substance of interest using the fusion peptide.
    Type: Application
    Filed: October 29, 2014
    Publication date: April 30, 2015
    Inventors: Jung Min Kim, Kyoung Hu Lee, Jae Il Lee, Jungmin Lee
  • Publication number: 20150118315
    Abstract: A finished pharmaceutical product adapted for oral delivery of an aromatic-cationic peptide, wherein the product comprises a therapeutically effective amount of the peptide; at least one pharmaceutically acceptable pH-lowering agent; and at least one absorption enhancer effective to promote bioavailability of the active agent. The product is adapted for use in a method for enhancing the bioavailability of a therapeutic aromatic-cationic peptide delivered orally.
    Type: Application
    Filed: June 13, 2012
    Publication date: April 30, 2015
    Applicant: Stealth Peptides International, Inc.
    Inventor: D. Travis Wilson
  • Patent number: 9018173
    Abstract: N-type voltage-gated calcium channels (CaV2.2) are critical mediators of neurotransmitter release and are thought to be involved with transmission of nociception. The use of conventional CaV2.2 blockers in pain therapeutics is limited by side effects. Reported herein is a means to suppress both inflammatory and neuropathic pain without directly blocking CaV2.2, but rather by inhibiting the binding of the axonal collapsin response mediator protein 2 (CRMP-2), a protein known to enhance CaV2.2 function. A 15 amino acid peptide of CRMP-2 fused to the protein transduction domain of the HIV tat protein (TAT CBD3) reduced meningeal blood flow induced by activation of the trigeminovascular system, prevented inflammation-induced tactile hypernociception induced by intraplantar formalin and nocifensive behavior following corneal capsaicin application, and reversed neuropathic hypernociception produced by the antiretroviral drug 2?,3?-dideoxycytidine. Preventing CRMP-2—mediated enhancement of CaV2.
    Type: Grant
    Filed: June 10, 2011
    Date of Patent: April 28, 2015
    Assignee: Indiana University Research and Technology Corp.
    Inventor: Rajesh Khanna
  • Publication number: 20150111836
    Abstract: The present invention provides methods, compositions and kits for modulating DSB repair processes in a subject in need thereof. More specifically, the invention provides the use of compounds that modulate the expression or activity of at least one APOBEC family member for modulating DSB repair processes.
    Type: Application
    Filed: February 12, 2013
    Publication date: April 23, 2015
    Inventors: Moshe Kotler, Roni Nowarski, Elena Britan-Rosich, Lea Baraz
  • Publication number: 20150110882
    Abstract: It is intended to provide a stable metallic nanostructure that causes no aggregation when surface-modified with biomolecule-reactive functional molecules. 30 to 90% of the surface of a metallic nanostructure is covered with at least one or more types of colloid-stabilizing functional molecules. The remaining portions on the surface of the metallic nanostructure are further covered with one or more types of biologically functional molecules.
    Type: Application
    Filed: October 18, 2013
    Publication date: April 23, 2015
    Applicants: JAPANESE FOUNDATION FOR CANCER RESEARCH, IMRA America, Inc.
    Inventors: Yuki Ichikawa, Kiyotaka Shiba
  • Patent number: 9012603
    Abstract: The invention relates to peptides which bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates to methods of using and methods of making the peptides of the invention.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: April 21, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Adam R. Mezo, Kevin A. McDonnell, Cristina A. Tan Hehir, Alfredo Castro
  • Publication number: 20150105336
    Abstract: Provided is a mucosa-elevating agent containing 0.1% to 1.0% of a peptide, wherein the peptide is an amphipathic protein having 8 to 200 amino acid residues in which hydrophilic amino acids and hydrophobic amino acids are alternately bonded, and is a self-assembling peptide that exhibits a ? structure in an aqueous solution at physiological pH and/or in the presence of cations.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 16, 2015
    Inventors: Kentaro Takamura, Satoru Kobayashi, Noriaki Matsuda
  • Publication number: 20150105334
    Abstract: The invention provides specific peptides derived from the cytotoxicity receptor NKp44 useful for preventing and treating serious diseases including in particular cancer. The invention further relates to compositions comprising a fragment of the extracellular region of NKp44 for preventing or treating cancer.
    Type: Application
    Filed: September 22, 2014
    Publication date: April 16, 2015
    Inventor: Angel PORGADOR
  • Publication number: 20150105335
    Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 16, 2015
    Inventor: Richard Franklin
  • Patent number: 8999939
    Abstract: A hair treatment agent having advantageous properties is provided. The hair treatment agent contains, based on weight of the agent, 0.00001 to ?0.05% by weight of at least one oligopeptide having at least one amino acid sequence Glu-Glu-Glu (formula (A)), wherein the amino group may be present in a free or protonated manner, and the carboxy groups may be present in a free or deprotonated manner.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: April 7, 2015
    Assignee: Henkel AG & Co. KGaA
    Inventors: Erik Schulze Zur Wiesche, Petra Westphal, Elisabeth Poppe
  • Patent number: 9000124
    Abstract: A polypeptide or multimeric polypeptide construct having the ability to bind to cMet or a complex comprising cMet and HGF, and methods for use are disclosed.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: April 7, 2015
    Assignees: Dyax Corp., Bracco Suisse SA
    Inventors: Daniel T. Dransfield, Aaron Sato, Robert Charles Ladner, Palaniappa Nanjappan
  • Patent number: 8999925
    Abstract: The present invention describes peptides which inhibit fusion of an arenavirus (e.g., Pichinde virus; PICV) with a host cell membrane. The arenavirus inhibiting (AVI) peptides described herein comprise a segment of the GP2 protein of an arenavirus. The AVI peptides are useful for inhibiting arenavirus-to-host cell membrane fusion and for treating arenavirus infections. In a particular embodiment, the arenavirus inhibiting peptide comprises a segment of PICV glycoprotein 2 (PICV GP2; SEQ ID NO: 1), Tamiami virus (TAMV) GP2 (SEQ ID NO: 14), or Lassa virus (LASV) GP2 (SEQ ID NO: 15). In particular, the segment is selected from a region of an arenavirus GP2 extending from the N-terminus into the first half of the FIR (i.e., from residues 1 through 105 of SEQ ID NO: 1, SEQ ID NO: 14, or SEQ ID NO: 15).
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 7, 2015
    Assignee: The Administrators of the Tulane Educational Fund
    Inventors: Jennifer S. Spence, Robert F. Garry
  • Publication number: 20150094272
    Abstract: The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
    Type: Application
    Filed: August 17, 2012
    Publication date: April 2, 2015
    Applicant: Ironwood Pharmaceuticals, Inc.
    Inventors: Marco Kessler, Angelika Fretzen, Hong Zhao, Robert Solinga, Vladimir Volchenok
  • Patent number: 8993531
    Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate protein kinase D (PKD) activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to cellular localization signals, epitope tags and/or reporters. The invention also includes polynucleotides encoding the ligands and polyligands.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: March 31, 2015
    Assignee: Intrexon Corporation
    Inventor: Thomas D. Reed
  • Publication number: 20150087597
    Abstract: Described herein are fragments of fibronectin and vitronectin and variants thereof that have certain activities, including growth factor-binding activity. Also described are fragments of growth factors that bind to fibronectin and inhibit binding of full-length growth factors to fibronectin. Compositions containing such fragments are useful in cosmetic treatments (e.g., the treatment of wrinkles or UV photodamage of skin), and the treatment of wounds and cancer.
    Type: Application
    Filed: May 1, 2014
    Publication date: March 26, 2015
    Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventor: Richard A. Clark
  • Patent number: 8980844
    Abstract: A peptide having antibacterial or anti-inflammatory activity and a pharmaceutical composition containing the same as an active ingredient are described. Also, a peptide having antibacterial or anti-inflammatory activity against dental bacteria, including periodontal pathogens, and bacteria causing atopic dermatitis, and a pharmaceutical composition containing the peptide as an active ingredient are described. The inventive peptide having antibacterial or anti-inflammatory activity can be used for the treatment of both dental infectious diseases, including periodontitis, and inflammations, including arthritis.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 17, 2015
    Assignee: Nano Intelligent Biomedical Engineering Corporation Co. Ltd.
    Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee
  • Patent number: 8980843
    Abstract: Peptides are provided having leptin receptor agonist activity. The peptides are useful for treating obesity, type II diabetes, appetite control after bariatric surgery, insulin resistance, lipodystrophy and hypothalamic amenorrhea, obesity-related infertility, among other diseases and conditions related to leptin deficiency and/or leptin resistance.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: March 17, 2015
    Assignee: Temple University—of the Commonwealth System of Higher Education
    Inventor: Laszlo Otvos, Jr.
  • Publication number: 20150071862
    Abstract: Functionalized fluorine containing phthalocyanine molecules, methods of making, and methods of use in diagnostic applications and disease treatment are disclosed herein. In some embodiments, the fluorine containing phthalocyanine molecules are functionalized with a reactive functional group or at least one cancer-targeting ligand (CTL). The CTL can facilitate more efficient binding and/or internalization to a cancer cell than to a healthy cell. The CTL can inhibit expression of oncoprotein in some embodiments. The pthalocyanine moiety can be used in diagnostic applications, such as fluorescence labeling of a cancer cell, and/or treatment applications, such as catalyzing formation of a reactive oxygen species (ROS) which can contribute to cell death of a cancer cell.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 12, 2015
    Inventors: David Sabatino, Sergiu M. Gorun, Emily Borland, Hemantbhai Patel, Pradeepkumar Patel
  • Publication number: 20150071856
    Abstract: The invention is in the field of molecular medicine. It provides antagonistic compounds for frizzled-1 and/or frizzled-2 receptors, which may be useful in molecular imaging of the wound healing process after myocardial infarction and in therapeutic intervention into wound healing after remodeling of the heart, thereby ameliorating the consequences of myocardial infarction. The invention provides a method for antagonizing frizzled-1 or frizzled-2 receptors, wherein the receptor is contacted with a composition comprising a linear fragment of Wnt3(a) or Wnt5a or a functional analogue thereof, which comprises at least one cysteine residue, one threonine residue, one aspartic acid residue and one glycine residue.
    Type: Application
    Filed: September 12, 2013
    Publication date: March 12, 2015
    Inventors: Wessel Matthijs Blankesteijn, Hilde Laeremans, Tilman Mathias Hackeng
  • Publication number: 20150072936
    Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.
    Type: Application
    Filed: May 21, 2014
    Publication date: March 12, 2015
    Inventors: Colleen M. Brophy, Alyssa Panitch, Catherine Parmiter, Elizabeth J. Furnish, Padmini Komalavilas
  • Patent number: 8974805
    Abstract: The present invention relates to a dental cleanser composition for improving adhesion to teeth, and more particularly to, a dental cleanser composition which functions to remove not only a smear layer from the dentin surface of an exposed tooth root, but also oral bacteria, and thus is effective in improving adhesion to teeth in periodontal surgery. The present invention provides a dental cleanser composition containing sodium ethylene diaminotetraacetate and octyl phenol ethoxylate which is a surfactant. Sodium ethylene diaminotetraacetate in the composition functions to remove a smear layer on the tooth root surface and has antibacterial activity, and octyl phenol ethoxylate in the composition functions to lipopolysaccharide. Thus, the composition improves adhesion to teeth in periodontal surgery.
    Type: Grant
    Filed: February 28, 2011
    Date of Patent: March 10, 2015
    Assignee: Nano Intelligent Biomedical Engineering Corporation
    Inventors: Chong-Pyoung Chung, Yoon-Jeong Park, Jue-Yeon Lee
  • Publication number: 20150065435
    Abstract: The present invention provides reagents and methods for treating dental disease.
    Type: Application
    Filed: May 25, 2012
    Publication date: March 5, 2015
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Mehmet Sarikaya, Martha Somerman, Candan Tamerler-Behar, Hanson Fong, Hai Zhang, Mustafa Gungormus
  • Publication number: 20150065424
    Abstract: The invention relates to composition comprising a pharmaceutically effective amount of one or more functional vasoactive intestinal peptide (VIP) fragments, and the use of those compositions in the treatment of fibrosis, hypertension and other disorder.
    Type: Application
    Filed: November 17, 2014
    Publication date: March 5, 2015
    Applicant: VECTUS BIOSYSTEMS LIMITED
    Inventor: Karen Annette Duggan
  • Publication number: 20150065414
    Abstract: The present invention provides modified TLR2 ligands useful for modulating inflammatory responses. In particular, the ligands comprise (a) a fatty acid di- or tri-linoleate and (b) a GM1-binding peptide. The linoleate provides the anti-inflammtory function, while the GM1-binding peptide facilitates endocytosis.
    Type: Application
    Filed: August 30, 2012
    Publication date: March 5, 2015
    Applicant: UTI LIMITED PARTNERSHIP
    Inventors: Elizabeth M. Long, Stephen M. Robbins, Paul Kubes, Ela Kolaczkowska
  • Patent number: 8969514
    Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: March 3, 2015
    Assignee: Synergy Pharmaceuticals, Inc.
    Inventor: Kunwar Shailubhai
  • Publication number: 20150057217
    Abstract: The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below wherein A1, v, A2, w, A3, x, y, A4, z, R1, R2 and R3 are as defined in the application; or a salt thereof. The invention further relates to use of the peptides as antibacterial agents, or antitumor agents, including the medical use of the peptide in treating infection and/or cancer, as well as their use as preservatives and antibacterial agents in other products, including personal care products such as skin topical treatments, cleansers, mouth washes, toothpastes, shampoo, body lotions and creams etc.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 26, 2015
    Inventors: Jian R. LU, Xiubo ZHAO, Fang PAN, Mohammed YASEEN
  • Patent number: 8961971
    Abstract: This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: February 24, 2015
    Assignees: Development Center for Biotechnology, DCB-USA LLC
    Inventors: Yu-Shen Hsu, Show-Shan Sheu, Ming-I Chang, Ming-Chuan Chang, Ta-Tung Yuan
  • Patent number: 8962571
    Abstract: A method for repairing DNA damage in human keratinocytes by applying to the keratinocytes a composition comprising at least one CLOCK or PER1 gene activator and at least one DNA repair enzyme.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: February 24, 2015
    Assignee: ELC Management
    Inventors: Daniel H. Maes, Nadine A. Pernodet, Lenny Slutsky, Donald F. Collins, Kerri Goldgraben, Edward Pelle, James Timothy McCarthy
  • Publication number: 20150051159
    Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 19, 2015
    Inventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodríguez Figueroa
  • Patent number: 8957185
    Abstract: Peptides from the MUC1 cytoplasmic domain and methods of use therefor are described. These peptides can inhibit MUC1 oligomerization, thereby preventing tumor cell growth, inducing tumor cell apoptosis and necrosis of tumor tissue in vivo.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: February 17, 2015
    Assignees: Dana-Farber Cancer Institute, Inc., Genus Oncology, LLC
    Inventors: Donald W. Kufe, Surender Kharbanda
  • Patent number: 8957013
    Abstract: The invention provides for a receptor, capable of binding to a target molecule, linked to a hygroscopic polymer or hydrogel; and the use of this receptor in a device for detecting the target molecule in a gaseous and/or liquid phase. The invention also provides for a method for detecting the presence of a target molecule in the gas phase using the device. In particular, the receptor can be a peptide capable of binding a 2,4,6-trinitrotoluene (TNT) or 2,4,-dinitrotoluene (DNT).
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: February 17, 2015
    Assignee: The Regents of the University of California
    Inventors: Justyn W. Jaworski, Seung-Wuk Lee, Arunava Majumdar, Digvijay A. Raorane
  • Patent number: 8957030
    Abstract: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: February 17, 2015
    Assignees: Cornell Research Foundation, Inc., Institute de Recherches Cliniques de Montreal
    Inventors: Hazel H. Szeto, Peter W. Schiller, Kesheng Zhao
  • Patent number: 8957026
    Abstract: The invention relates to ?-catenin targeting peptides comprising an ?-helical segment that are optionally stapled or stitched, and pharmaceutical compositions thereof. Uses of the inventive ?-catenin targeting polypeptides including methods for treatment of disease, such as diseases associated with aberrant Wnt signaling, including cancer, are also provided.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: February 17, 2015
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Tom N. Grossmann, Tsung-Han Johannes Yeh
  • Publication number: 20150045310
    Abstract: Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.
    Type: Application
    Filed: February 4, 2013
    Publication date: February 12, 2015
    Inventors: A. James Link, Siyan Zhang
  • Patent number: 8951975
    Abstract: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: February 10, 2015
    Assignee: OncoTherapy Science, Inc.
    Inventors: Yusuke Nakamura, Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura, Tomohisa Watanabe
  • Patent number: 8951527
    Abstract: Described herein is the discovery that cell and tissue survival can be dramatically increased following radiation exposure through inhibition of the interaction between TSP-1 and CD47. This effect is shown using antisense molecules, peptides, and antibodies, which can now be used as radioprotectant agents. These agents find application in minimizing, reducing and/or preventing tissue damage following intentional and accidental radiation exposure, as well as increasing the therapeutic efficacy of radiation therapies by protecting non-target tissue from incidental radiation damage and by increasing tumor ablation following radiation treatment.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: February 10, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey S. Isenberg, David D. Roberts, Justin Maxhimer
  • Patent number: 8951963
    Abstract: The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: February 10, 2015
    Assignee: Drexel University
    Inventors: Irwin M. Chaiken, Umashankara Muddegowda, Karyn McFadden
  • Patent number: 8951974
    Abstract: Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following amino acid sequence: a1b1c1b2a2b3 db4a3b5c2b6a4 where: a1 to a4 each represent a basic amino acid residue; b1 to b6 each represent an uncharged polar amino acid residue and/or a hydrophobic amino acid residue, provided that at least five thereof each represent a hydrophobic amino acid residue; c1 and c2 each represent an acidic amino acid residue; and d represents a hydrophobic amino acid residue.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: February 10, 2015
    Assignees: Menicon Co., Ltd., National University Corporation Okayama University
    Inventors: Yusuke Nagai, Hidenori Yokoi, Koji Uesugi, Keiji Naruse
  • Publication number: 20150037376
    Abstract: Methods and compositions for oral administration of melanocortin receptor agonist compounds are disclosed herein. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of sexual dysfunction, including male sexual dysfunction and female sexual dysfunction. Methods and compositions for oral administration of melanocortin receptor agonist compounds are provided for treatment of metabolic syndrome, obesity and/or diabetes. In some embodiments, a pharmaceutical composition comprising a peptide-based melanocortin receptor agonist, a protease inhibitor, an absorption enhancer is administered orally.
    Type: Application
    Filed: November 2, 2012
    Publication date: February 5, 2015
    Inventors: Gaurav Seth, Natan Bar-Chama
  • Patent number: 8946383
    Abstract: The present invention relates to obtaining bioactive peptides from plant raw materials, specifically cocoa extracts, by means of enzyme treatment. Said biopeptides have angiotensin converting enzyme (ACE) and prolyl endopeptidase enzyme (PEP) inhibitory activity in vitro and/or antioxidant activity in vivo, being able to be used in the food, dietetic and pharmaceutical industry.
    Type: Grant
    Filed: August 1, 2008
    Date of Patent: February 3, 2015
    Assignee: Naturex
    Inventors: Begoña Muguerza Marquínez, Honorato Monzo Oltra, Natalia Alepuz Rico, Esther Bataller Leiva, Salvador Genoves Martínez, Maria Enrique López, Patricia Guerola Guerola, Daniel Ramon Vidal